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Abstract: The body responds to endotoxins by triggering the acute inflammatory response system
to eliminate the threat posed by gram-negative bacteria (endotoxin) and restore health. However,
an uncontrolled inflammatory response can lead to tissue damage, organ failure, and ultimately
death; this is clinically known as sepsis. Mathematical models of acute inflammatory disease have the
potential to guide treatment decisions in critically ill patients. In this work, an 8-state (8-D) differential
equation model of the acute inflammatory response system to endotoxin challenge was developed.
Endotoxin challenges at 3 and 12 mg/kg were administered to rats, and dynamic cytokine data for
interleukin (IL)-6, tumor necrosis factor (TNF), and IL-10 were obtained and used to calibrate the
model. Evaluation of competing model structures was performed by analyzing model predictions at
3, 6, and 12 mg/kg endotoxin challenges with respect to experimental data from rats. Subsequently,
a model predictive control (MPC) algorithm was synthesized to control a hemoadsorption (HA)
device, a blood purification treatment for acute inflammation. A particle filter (PF) algorithm was
implemented to estimate the full state vector of the endotoxemic rat based on time series cytokine
measurements. Treatment simulations show that: (i) the apparent primary mechanism of HA efficacy
is white blood cell (WBC) capture, with cytokine capture a secondary benefit; and (ii) differential
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filtering of cytokines and WBC does not provide substantial improvement in treatment outcomes vs.
existing HA devices.
Keywords: mathematical model; inflammation; cytokines; sepsis; endotoxemia; hemoadsorption;
nonlinear MPC; particle filter; state estimation
1. Introduction
1.1. Inflammation
Inflammation is the body’s natural response to infection and trauma [1]. Macrophage cells
play a key role in the initiation and orchestration of the inflammatory response. These immune
cells reside in tissues where they monitor the environment for molecules derived from pathogen or
damaged cells [2]. When such molecular patterns are detected, macrophages secrete pro-inflammatory
mediators (such as tumor necrosis factor (TNF) and interleukin (IL)-1) and chemoattract other
WBCs, thus initiating an immune response [3]. TNF and IL-1 induce endothelial cells to express
adhesion molecules for neutrophils, a circulating white blood cell. Neutrophils migrate into the
tissues, following chemokine gradients, where they scavenge and digest pathogen in a process
called phagocytosis [4]. Pro-inflammatory cytokines also trigger an anti-inflammatory wave that
suppresses inflammation and returns the system to baseline as the infection or damage is cleared [5].
IL-10 is a powerful anti-inflammatory cytokine that suppresses the expression of pro-inflammatory
cytokines and the activity of innate immune effector cells [6]. Anti-inflammation is an essential
regulator of the inflammatory response that thwarts potential deleterious cytotoxic effects of vigorous
pro-inflammation. Although the goal of the inflammatory response is to contain and eliminate the
initial biological stressor (e.g., infection) and thus restore a healthy state, it also has the potential to push
the system into a number of pathological states. Case in point, high levels of anti-inflammatory IL-10 in
combination with pro-inflammatory IL-6 have been associated with risk of death in septic patients [7].
1.2. Sepsis
Sepsis, a systemic inflammatory response triggered by infection, is one such pathology [8].
An estimated 751,000 incidents of severe sepsis occur annually in the United States with 51% of cases
receiving treatment in the ICU and 28.6% mortality [9]. Severe sepsis may lead to the failure of multiple
organ systems [10]. The cascade of organ failures may occur even while the infection is suppressed by
antibiotics, demonstrating that uncontrolled inflammation is destructive to organ tissues.
The mainstay of sepsis treatment has been source control, antibiotic treatment, fluid resuscitation
and organ support. Recent recommendations added very few additional options to this therapeutic
approach [11,12]. Numerous attempts at controlling the ill effects of the inflammatory response in sepsis
using immunomodulation, such as anti-inflammatory treatments (e.g., anti-TNF antibodies, low dose
corticosteroids, etc.), have largely failed to improve patient outcome despite great pre-clinical promise.
Hence, there is ongoing controversy as to the merit of immunomodulation in severe sepsis [12,13] and
reticence to pursue development of interventions based on simple rationales. An opportunity exists
for model-based intervention design in sepsis and other complex diseases where standard approaches
have not delivered expected advances.
1.3. Mathematical Models of Inflammation
Our previous work focused on either low-order [14] phenomenological or high-complexity [15–17]
models of the inflammatory response cascade. Other groups have also attacked the problem of
modeling inflammatory processes [18–25]. More complex models increase biologic accuracy at the
expense of full structural and parameter identifiability. The mapping of such complex models to data
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requires either significant amounts of data at a variety of scales or resolutions (some of which may
not be experimentally measurable using current methods) or assumptions about the mathematical
structure and relationships between parameters and/or variables. In contrast, low-order models
may over-simplify the biology (e.g., “inflammation” vs. explicit cytokine equations), but formal
mathematical analysis is facilitated by such structures. Our previously-developed low-order model [14]
consisted of an inflammatory stimulus (pathogen) and early-and-late pro-inflammatory mediators
which captured a variety of clinically relevant scenarios, including return to health, sterile death
(pathogen free), and septic death (pathogen overload). We later extended the model by incorporating
anti-inflammatory mediators, based on their value in restoring health and preventing sterile death [26].
Although these models provided insight into key drivers of inflammatory response outcome, they only
qualitatively described inflammation response and were not calibrated to experimental data. Hence,
the existing low-order models are not quantitatively predictive, nor would they be appropriate for use
in treatment design where quantitative understanding of cytokine dynamics and how to modify such
a response is needed.
1.4. Endotoxemia: A Model of Sepsis
Bacterial endotoxin is a key and highly conserved component of the cell wall of a large number of
bacteria responsible for sepsis. The immune system promptly recognizes and responds to bacterial
endotoxin initiating a vigorous, cytokine-mediated systemic inflammatory response that is highly
reproducible and similar to the response observed in sepsis, including fever, low blood pressure, and
accelerated respiratory and cardiac rates. In high doses, endotoxin may lead to organ dysfunction and
death. Administration of endotoxin in laboratory animals serves as a laboratory model of sepsis and
acute inflammation [27,28].
1.5. Hemoadsorption: A Potential Treatment for Sepsis
Hemoadsorption (HA) is a blood purification treatment that has been shown to improve
short term survival in septic rat models, presumably through nonspecific removal of inflammatory
mediators [29,30]). A portion of the septic animal’s blood is circulated through an ex vivo circuit
including the HA device: a column packed with small adsorptive beads. Key inflammatory cytokines
responsible for the propagation of the inflammatory response, including TNF, interleukin(IL)-6,
and IL-10, are captured by the device [29]. A calibrated model of cytokine capture was presented
by DiLeo et al. [31,32] There is preliminary evidence that existing HA devices directly interact with
circulating WBCs, the distal effectors of systemic inflammation. Research is ongoing to characterize
the specific nature of the interaction between the HA device and subpopulations of WBCs [33].
1.6. Model-Based Treatment
Models of acute inflammation have potential to guide treatment decisions. The endotoxemia
model in Section 2.2 predicts WBC activation, cytokine levels and tissue damage following an endotoxin
challenge. System response to external perturbations of model variables, including cytokines TNF,
IL-6 and IL-10, is captured through the interactions modeled in Section 2.2. When the effect of
treatment on a model variable can be quantified, the system response can be predicted. HA treatment,
which captures cytokines and potentially WBCs, is an ideal candidate for such exploration since its
effect on model variables can be quantified.
The effect of HA will be dependent on the underlying inflammatory state. Consequently, an ideal
treatment strategy might adapt in response to changes in the subject’s health. Adaptive treatment
requires two components: a method for choosing an appropriate treatment regimen based on the
inflammatory state; and a method of identifying the inflammatory state based on noisy and sparse
measurements. Control theoretic methods provide a solution to the first problem, while state estimation
techniques address the second.
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1.6.1. Model Predictive Control
Model predictive control (MPC) is a popular control methodology for addressing biomedical
systems control problems [34,35], based on its ability to robustly manage subject-model mismatch
in a variety of disease case studies. MPC uses the predictive capacity of a model to manipulate
inputs and guide a dynamic process towards a target trajectory [36]. MPC is a receding finite horizon
method, where the control decision is based only on the predicted trajectory over a finite time window
(i.e., horizon). As time advances, the horizon slides and new control decisions are based on the
latest system observations. In the case of acute illness, MPC of HA could maintain homeostasis
and guide the patient to health based on observations of biomarkers and vital signs. MPC has been
applied towards the modulation of acute inflammation in the context of a four equation model of
pathogen infection [37].
1.6.2. State Estimation: Mapping Diagnostics into Model Representations
In clinical application, state estimation corresponds to the process of translating patient
diagnostic measurements into state information using a model-based description that is suitable
for predicting outcomes and selecting treatments. It is impractical or even impossible to measure
every variable represented in the endotoxemia model. Measuring serum cytokines in blood samples
is straightforward, although sampling frequency and noise limit resolution. In contrast, there is no
direct way to measure abstract states such as tissue damage (D) and long acting anti-inflammatory
meditators (CA). Consequently, a method of estimating the model state based on partial and noisy
observations is necessary. Rawlings and Bakshi describe a variety of methods for nonlinear state
estimation in the context of MPC [38].
The Particle filter (PF) is a stochastic state estimation method described as “survival of the
fittest” [39], which can also be used in parameter estimation. A number of parallel simulations
(“particles”) are randomly initialized from a prior distribution of states. Following an observation,
simulations are weighted by the posterior probability that the observation was generated by the particle.
The particles are then resampled (with replacement) from the weighted distribution, and the resampled
particle simulations are evolved dynamically to the next observation time point. The expected state
values are calculated as the weighted average of the particle states. PF is appealing due to its generality
and ease of implementation, though computational effort may be prohibitive in complex models.
Nonlinear models with non-Gaussian noise distributions, such as the endotoxemia model, are notable
candidates for PF application.
1.7. Manuscript Overview
In this work, we synthesize an intermediate-order model of acute inflammatory response
to endotoxin challenge and calibrate the model parameters to data from rat studies.
Major pro-inflammatory cytokines, like IL-6 and TNF, as well as anti-inflammatory cytokines, like IL-10
and CA (a biologically-motivated lumped surrogate representing slow acting anti-inflammatory
mediators, such as the Transforming Growth Factor-β1 (TGF-β1) cytokine and cortisol) were
incorporated in the model. Similar to [26], a non-measurable tissue damage marker was also included
in the model to quantify the tissue damage caused due to the endotoxin challenge and activated
phagocytic cells (N). The modeling objective of this work was to ground the intermediate inflammatory
response model in experimental data, thereby providing a model that captures the dynamic blood
concentrations of the major pro- and anti-inflammatory cytokines resulting from introduction of an
endotoxin challenge (P(t)) in rats. Using the model explicitly, a model-based treatment design system
is constructed using the MPC framework. A PF is used to estimate the current state, for use in tailoring
hemofiltration treatment to inflammatory response. The closed-loop system is evaluated in silico for its
ability to control cytokine levels after pro-inflammatory endotoxin challenge.
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2. Materials and Methods
2.1. Experimental Data
Experiments on three cohorts of Sprague-Dawley rats were performed, in accordance with
an IACUC-approved protocol at the University of Pittsburgh, to study the acute inflammatory response
to endotoxin insults at various dose levels. Rats weighed approximately 200 g, and rats received
endotoxin (Escherichia Coli) at dose levels of either 3, 6, or 12 mg/kg, intraperitoneally. Blood samples
were collected when rats were sacrificed at 0, 1, 2, 4, 8, 12, and 24 h after endotoxin administration
(4 rats sacrificed per time point per endotoxin dose level). Concentrations of IL-6, IL-10, and TNF
were measured in triplicate using commercially available ELISA kits (R & D Systems, Minneapolis,
MN, USA).
2.2. Mathematical Model of Acute Inflammation
The starting point for the present model comes from [26], a 4-state phenomenological description
of the inflammatory response process.
dP(t)
dt
= kpgP(t)
(
1− P(t)
p∞
)
− kpmsmP(t)
µm + kmpP(t)
− kpn f (N∗(t))P(t) (1)
dN∗(t)
dt
=
smR
µnr + R
− µnN∗(t) (2)
dD(t)
dt
= kdn fs( f (N∗(t)))− µdD(t) (3)
dCA(t)
dt
= sc +
kcn f (N∗(t) + kcndD(t))
1+ f (N∗(t) + kcndD(t))
− µcCA(t) (4)
Here
R = f (knnN∗(t) + knpP(t) + kndD(t))
f (V) =
V
1+
(
CA(t)
c∞
)2
fs(V) =
V6
x6dn +V
6
Pathogen, P, induces inflammatory response leading to activated phagocytic cells, N∗. This cell
activation leads to pathogen death and also tissue damage, D. Moderation of the inflammatory
response is provided by anti-inflammatory mediators, represented by CA. This abstract model of
the inflammatory response to pathogen provides multiple steady states and the ability to achieve
clinically-relevant states of recovery (low P and D at long time), septic sepsis (high P and D at long
time), and aseptic sepsis (high N∗ and D, but P = 0, at long time).
The acute inflammation model developed herein consists of eight ordinary differential equations
(ODEs). The dependent variables used in the model include: endotoxin concentration (P(t));
total number of activated phagocytic cells (N(t)), which includes all the activated immune
response cells (such as neutrophils, monocytes, etc.); a non-accessible tissue damage marker (D(t));
concentrations of pro-inflammatory cytokines IL-6 ([IL6]) and TNF ([TNF]); concentration of the
anti-inflammatory cytokine IL-10 ([IL10]); a tissue damage driven non-accessible IL-10 promoter
(YIL10(t)); and a non-accessible state representing slow acting anti-inflammatory mediators (CA(t)).
A schematic diagram of the model capturing all the major interactions between the eight
states is shown in Figure 1. Introduction of P into the system activates N. Once activated,
N up-regulates production/release of all the inflammatory mediators (TNF, IL-6, IL-10, and CA) [40].
The pro-inflammatory cytokines have a positive feedback on the system; thereby, they further activate
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N, and up-regulate other cytokines [40,41]. On the other hand, the anti-inflammatory cytokine and
mediators have a negative feedback on the system. Hence, IL-10 and CA inhibit the activation of N and
up-regulation of other cytokines [42,43]. Mathematically, CA also serves to provide overall stability to
the model (i.e., a low standing level of CA, serves to return inflammation to its baseline value after
small perturbations). The model also incorporates tissue damage due to activated phagocytic cells,
represented by a damage marker, D; this corresponds biologically to neutrophil-induced damage to
lung tissue after a systemic inflammatory response. Tissue damage further up-regulates activation of
N [44] and also contributes to up-regulation of IL-10 [45,46].
P
D N
IL−6
IL−10
C
Downregulate
Upregulate
TNF
A
Figure 1. Schematic diagram of inflammatory response system challenged by endotoxin.
The endotoxin insult is injected intraperitoneally in the rats as a bolus administration,
which initiates the inflammatory cascade. The ODE describing the dynamics of P(t) can be written as:
dP(t)
dt
= −dPP(t) (5)
P(t) decays exponentially with a rate equal to dP. The decay rate was fixed at 3 h−1, which is
consistent with the values obtained from published literature [47–49]. The initial conditions (t = 0) for
Equation (5) are either 3, 6, or 12 mg/kg depending on the endotoxin dose level.
Resting phagocytic cells are activated by the presence of endotoxin in the system. The equations
representing activation of N(t) can be mathematically written as:
dN(t)
dt
= kN
R(t)
xN + R(t)
− dN N(t) (6)
R(t) = [kNPP(t) + kNDD(t)] (1+ kNTNF f UPNTNF(t))
(1+ kNIL6 f UPNIL6(t)) f DNNCA(t) f DNNIL10(t)
(7)
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f UPNTNF(t) =
[TNF]
xNTNF + [TNF]
(8)
f UPNIL6(t) =
[IL6]
xNIL6 + [IL6]
(9)
f DNNCA(t) =
xNCA
xNCA + CA(t)
(10)
f DNNIL10(t) =
xNIL10
xNIL10 + [IL10]
(11)
Here, Equation (6) represents the total number of activated phagocytic cells (N(t)). Parameters kN
and dN represent the rate of activation and elimination of N(t), respectively. Activation of N(t)
is driven by P(t) and D(t), through R(t), as shown in Equation (7). Throughout this work,
functions with nomenclature f UPij(t) and f DNij(t) represent up-regulating (UP) and down-regulating
(DN) effects of inflammatory mediator j on mediator i. These up- or down-regulating functions are
dimensionless and bounded, having values between 0 and 1. Functions, f UPNTNF(t) and f UPNIL6(t)
indicate the up-regulating effects of [TNF] and [IL6] on N(t), respectively. Both these functions are
Michaelis-Menten type equations, as shown in Equations (8) and (9). As the concentrations increase,
the values of the up-regulating functions also increase, approaching 1 asymptotically. Gain parameters
kNTNF and kNIL6 scale the up-regulating functions f UPNTNF(t) and f UPNIL6(t) to capture the
appropriate effects on N(t), respectively. The inhibitory effects of CA(t) and [IL10](t) are captured
by the down-regulating functions f DNNCA(t) and f DNNIL10(t), respectively. Here, as the variables
increase, the values of the functions decrease, approaching 0 asymptotically (see Equations (10)
and (11)). Parameters xN , xNTNF, xNIL6, xNCA, and xNIL10 are the half-saturation constants determining
the concentration level of the variables at which the corresponding up-regulating or down-regulating
function will reach half of its saturation point. The initial condition (t = 0) for Equation (6) is N(0) = 0.
The tissue damage caused by the inflammatory response to endotoxin challenge is modeled
as follows:
dD(t)
dt
= kD
N(t)6
x6D + N(t)
6
− dDD(t) (12)
Parameters kD and dD represent the rate of generation and the rate of elimination of the
unobserved tissue damage marker, D(t). Elevated D(t) further contributes to the activation of
N(t) (7) [44] and production of IL-10 [45,46]. Parameter xD is the half-saturation constant. A 6th-order
Hill function was utilized in order to accurately capture the data. Further explanation regarding the
choice of the Hill function coefficient is provided in the Appendix A. The initial condition (t = 0) for
Equation (12) is D(0) = 0.
The anti-inflammatory mediator, CA(t), represents a combination of various inflammation
inhibitory mediators, including the cytokine Transforming Growth Factor-β1 (TGF-β1) and cortisol.
The CA(t) equation is written as:
dCA(t)
dt
= kCAN(t)− dCACA(t) + sCA (13)
Parameters kCA and dCA represent the rate of CA(t) production/secretion and clearance,
respectively. At basal conditions, the system is assumed to be slightly anti-inflammatory. This was
achieved by introducing a constant, sCA, into Equation (13). Hence, at t = 0 and N(0) = 0, CA(0) =
sCA
dCA
.
The dynamics of IL-6, which is predominantly considered a pro-inflammatory mediator, can be
mathematically written as:
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d[IL6](t)
dt
= kIL6
(
(N(t))4
x4IL6 + (N(t))
4
)
[1+ kIL6TNF f UPIL6TNF(t) (14)
+kIL6IL6 f UPIL6IL6(t)] f DNIL6IL10(t)− dIL6[IL6](t)
f UPIL6TNF(t) =
([TNF](t))4
x4IL6TNF + ([TNF](t))
4
(15)
f UPIL6IL6(t) =
[IL6](t)
xIL6IL6 + [IL6](t)
(16)
f DNIL6IL10(t) =
xIL6IL10
xIL6IL10 + [IL10](t)
(17)
The up-regulation of IL-6 production is governed by activated N(t). Production of IL-6 is
further up-regulated by the presence of elevated [TNF](t) and [IL6](t) itself, and this is captured
by the up-regulating functions f UPIL6TNF and f UPIL6IL6(t), respectively. The inhibitory effects
of the anti-inflammatory cytokines were captured by the down-regulating function f DNIL6IL10(t).
The clearance rate of IL-6 is represented by the parameter dIL6(t). Once again, Section A further
explains the selection of the Hill function coefficient. Parameters xIL6, xIL6TNF, xIL6IL6, and xIL6IL10
are the half-saturation constants. The initial condition (t = 0) for Equation (15) is [IL6](0) = 0.
Pro-inflammatory TNF concentration can be represented by the following equations:
d[TNF](t)
dt
= kTNF(N(t))1.5 f DNTNFCA(t) f DNTNFIL6(t)− dTNF[TNF](t) (18)
f DNTNFCA(t) =
x6TNFCA
x6TNFCA + (CA(t))
6
(19)
f DNTNFIL6(t) =
xTNFIL6
xTNFIL6 + [IL6](t)
(20)
The rate of production of TNF due to activation of N(t) is governed by the parameter kTNF,
and the rate of clearance of TNF is represented by the parameter dTNF. A power of 1.5 was assigned to
N(t) instead of a Michaelis-Menten or Hill type expression in order to capture the rapid production
and elimination of TNF. Further justification for the proposed [TNF]-state (Equation (18)) is provided
in Appendix A. The function f UPTNFTNF(t) represents the up-regulating effect of [TNF](t) on its
own production. The functions f DNTNFCA(t) and f DNTNFIL6(t) represent the inhibitory effect of
anti-inflammatory cytokine CA(t) and pro-inflammatory cytokine IL-6 (which in some instances,
such as this, acts as an anti-inflammatory mediator [50]), respectively. Parameters xTNFTNF, xTNFCA,
and xTNFIL6 are the half-saturation constants. A 6th-order Hill function for f DNTNFCA(t) modeled
the rapid suppression of CA on the [TNF](t) dynamics. The initial condition (t = 0) for Equation (18) is
TNF(0) = 0.
The dynamics of [IL10](t), which is a strong anti-inflammatory cytokine, can be represented by
the following equations:
d[IL10]
dt
= kIL10
(
(N(t))3
x3IL10 + (N(t))
3
)
[1+ kIL10IL6 f UPIL10IL6(t)] (21)
−dIL10 f DNIL10IL10(t)[IL10](t) +YIL10(t) + sIL10
dYIL10(t)
dt
= kIL10Y
(D(t))4
x4IL10Y + (D(t))
4
− dIL10YYIL10(t) (22)
f UPIL10IL6(t) =
([IL6](t))4
x4IL10IL6 + ([IL6](t))
4
(23)
f DNIL10IL10(t) =
xIL10IL10
xIL10IL10 + [IL10](t)
(24)
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Here, Equation (22) captures the circulating [IL10](t) levels. Unlike the other measured cytokines,
the [IL10](t) dynamics demonstrate two distinct peaks separated by approximately 4 to 6 h when
perturbed by endotoxin challenge. The first surge of IL-10 production is predominantly attributed
to N(t), which is captured by a 3rd-order Hill equation multiplied by the parameter kIL10 (first RHS
term of Equation (22)). Production of IL-10 is further up-regulated by the presence of elevated
pro-inflammatory cytokines like IL-6, which is represented by the up-regulation function f UPIL10IL6(t).
The production of IL-10 in the basal state is represented by the constant sIL10 (as observed in
experimental data). Hence, at t = 0 and N(0) = 0, [IL10](0) = sIL10·xIL10IL10
(dIL10xIL10IL10−sIL10) . It has been shown that
the rate of elimination of IL-10 is inversely proportional to circulating [IL10](t) [51]. This phenomenon
is captured by a down-regulating function, f DNIL10IL10(t), coupled with the parameter dIL10, as
shown in Equation (22). Further discussion of the Equation (22) structure is presented in Appendix A.
The second surge in IL-10 production is attributed to tissue damage D(t) [45,46], and the dynamics
of this D-induced effect are captured by the variable YIL10(t) in Equation (22). The dynamics of YIL10(t)
are represented by the ODE (22); here the rate of production of YIL10(t) is represented by the parameter
kIL10Y coupled with a 4th-order Hill equation (first term in RHS of Equation (22)), which is driven
by D(t). Once again, this is data-motivated (see the further discussion in Appendix A). The rate of
elimination of YIL10(t) is given by parameter dIL10Y. Parameters xIL10, xIL10Y, xIL10IL6, and xIL10IL10
are the half-saturation constants.
The model developed above is a simplification of our earlier model [27,52] that eliminates
nonlinear up- and down-regulatory functions that did not display significant dynamics over the
endotoxin challenge range employed here. The parameter values used here are those published in
Table 1 of [27]. Alternative modeling options for the various interactions are discussed in Appendix A.
2.3. Parametric Sensitivity by Finite Difference Method
The model parameters in Equations (5)–(24) will vary in their effect on state and output
dynamics as a function of operating state and time. Sensitivity analysis, as calculated by finite
difference [53,54], is employed to identify the model parameters that have significant impact on model
predictions. Though local, this knowledge can be used to inform the design of future experiments for
elucidating model dynamics and parameter values. A drawback of finite difference-based sensitivity
analysis is that the information is not global, but the constrained nature of the parameter region
(e.g., parameter estimates will not change sign) makes global analysis highly conservative and beyond
the scope of the present study.
The inflammation model can be expressed as a set of Qx differential equations with Qx states (x)
and M parameters (θ). The Qx by M parameter sensitivity matrix can be calculated by using the finite
difference approximation method, in which the sensitivity coefficients (si,j) are calculated from the
difference of nominal and perturbed solutions [53,54], as follows:
si,j(t) =
∂xi(t)
∂θj
=
xi(θj + ∆θj, t)− xi(θj, t)
∆θj
(25)
Here, i ∈ [1, Qx], j ∈ [1, M]. To facilitate direct comparison of responses across different parameters,
normalized sensitivity coefficients (s¯i,j(t)) are calculated [53]:
s¯i,j(t) =
∂xi(t)
∂θj
θj
xi
(26)
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For the evaluation of dynamic sensitivity, an L2-norm operation is performed to calculate the
relative sensitivity (RS) aggregated over time. RS can be mathematically expressed as:
RSi,j =
1
QT
√√√√ QT∑
k=1
|s¯i,j(tk)|2 (27)
Here, tk (k ∈ [1, QT ]) are the times when a sample was collected, and QT is the number of sample
points observed for a given entity (e.g., [IL6](t), [TNF](t), etc.).
2.4. In Silico Treatment
Rat endotoxemia was simulated using the calibrated model equilibrated with zero endotoxin,
and then stimulated with P = 3–12 mg/kg endotoxin at t = 0. A hemoadsorption device model
(Section 2.7) was coupled to the endotoxemia model to simulate blood purification treatment via
the capture of cytokines and cells from the blood. Figure 2A illustrates the coupling mechanism
between the endotoxemia model and the HA device. The flow rate of blood through the device was
the manipulated variable in subsequent control simulations.
Figure 2. (A) Diagram of endotoxemia model coupled to a hemoadorption (HA) device model. N,
interleukin (IL)-6, tumor necrosis factor (TNF) and IL-10 are assumed to circulate through the ex vivo
HA circuit. Cytokine capture is modeled in a two step process: reversible diffusive entry into bead
pores, followed by irreversible binding to the internal bead surface. White blood cell (WBC) capture is
treated as reversible binding at the bead surface. (B) Schematic of in silico HA control experiments
without state estimation. Subject is modeled by the deterministic endotoxin model. Complete state
information is passed to the controller once per hour. (C) Schematic of in silico HA control experiments
with PF state estimation. Subject is modeled by the stochastic endotoxin model. State estimates are
based on noisy cytokine measurements obtained once per hour.
2.5. Stochastic Endotoxemia Model
A stochastic variant of the endotoxemia model was constructed by supplementing the
deterministic model with a geometric noise process. The stochastic equation for each state xi was:
dxi(t) = fi(~x(t))dt + σxi(t)dWt
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where ~x is the state vector,Wt is a Wiener process, and fi(~x(t)) is the deterministic derivative function.
Process noise was applied independently to each state variable. The stochastic model was integrated
using the Euler-Maruyama method:
xi(t + ∆t) =
∫ t+∆t
τ=t
fi(~x(τ))dτ + xi(t)N (0, σ2∆t).
All stochastic simulations were performed with σ = 0.05/h and ∆t = 0.1 h. The deterministic
component was integrated for control simulation purposes using the SUNDIALS CVODE library [55].
2.6. Observation Model
Observations of cytokines IL-6, TNF and IL-10 were generated from the distribution
Yi (xi) ∼ log-N (µi (xi) , σi). Under the assumption that cytokine state xi = E[Yi(xi)], we obtain:
µi(xi) = log(E[Yi(xi)])− σ2i /2 = log(xi)− σ2i /2.
Due to the limited number of samples obtained from experiments, σi is assumed to be independent
of state value. For each cytokine i, σi was computed as the time and dose averaged standard deviation
of log-measurements. The resulting noise parameters were σIL6 = 0.26, σTNF = 0.20, and σIL10 = 0.22.
2.7. Hemoadsorption Model
The HA device, a schematic of which is shown in Figure 2, is modeled using a spatial discretization
(n = 20) approximation of the partial differential equation to yield a set of ordinary differential equations.
Discretization for each cytokine was modeled using the following equations:
dCi(t)
dt
=
Fd
Vd
(Ci−1(t)− Ci(t))− kadCi(t) + VsVd kdesSi(t) (28)
dSi(t)
dt
=
Vd
Vs
kadCi(t)− (kdes + kbnd)Si(t) (29)
The fluid volume of a discretization is given by Vd, and the fluid flow through the HA device is
given by Fd. The first right-hand side term of Equation (28) models convection through the device,
with entering concentration Ci−1(t) and exiting concentration Ci(t), assuming the liquid in a given
discretization is well mixed. The last two terms capture cytokine adsorption to, and desorption from,
the bead bed surface. Adsorption and desorption here represent reversible capture at/near the bead
surface, with surface concentration Si defined by Equation (29). The last constant in Equation (29),
kbnd, represents irreversible uptake of cytokine into the bead pores . In order to keep the k’s in rate
units (1/min), the volume to surface area correction VsVd = 73.3 cm
−1 was used. The experimental data
was generated using a device flow rate of Fd =0.8 cm3/min.
Parameter identification was performed using the system dynamic model in Equations (28)
and (29). The inlet to the first liquid discretization came from the cytokine bath (a continuously-stirred
tank), and the liquid outlet of the 20th discretization was returned to the bath; additional experimental
details can be found in [56]. The initial concentration of cytokines in each HA device discretization was
0 pg/mL. Least-squares optimization was used to fit the parameters kad, kdes, and kbnd independently
for each cytokine. Parameter values can be found in Table 1. For validation, a low flow rate
(Fd =0.08 cm3/min) simulation was executed with no change in adsorption parameters, and the
output was compared to data for IL-6 [32] (figure not shown). The simulated bath concentration was
within the spread of the experimental data at all time points.
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Table 1. Best-fit parameter values (units of min−1) for the HA device.
IL-6 TNF IL-10 N
kad 0.62 0.188 0.682 0.177
kdes 0.013 0.015 0.072 0.010
kbnd 0.006 0.007 0.022 0
2.8. WBC Capture Model
Fifteen mL of heparin treated blood, obtained from septic or healthy donors, was circulated
through a 1.5 mL HA or sham device. WBC counts were obtained at the start of the experiment and
following 4 h of circulation through the device at 0.75 mL/min via a closed miniaturized extracorporeal
circuit. At 4 h, WBC counts in septic blood fell to 27% of baseline with the HA device versus 71%
with the sham device (N = 21). Similarly, WBC counts in healthy blood fell to 34% versus 82% of
baseline with HA and sham device, respectively (N = 5). Experimental details and additional results
are published [57,58].
A simple model of HA cell capture was calibrated to WBC differentials measured in septic blood.
We utilized the form of the cytokine capture model, but assumed that cell binding was reversible
(i.e., kbnd = 0). WBC counts in the sham circuit were used to calibrate a first-order WBC decay constant
that was applied to both sham and HA circuits. Parameters kad and kdes were calibrated to WBC
differentials in the HA circuit under a least squares criterion. Since only one differential was measured
for HA, many parameter pairs satisfied the best-fit criterion. Preferring an underestimate of the cell
capture rate, we chose kad to be slightly larger than the minimum possible value.
2.9. HA Device Configurations
The four HA device configurations simulated in this study are described in Table 2.
Configuration A corresponds to a 1.5 mL device with experimentally calibrated capture of cytokines
TNF, IL-6 and IL-10. Device B assumes that, in addition to cytokines, activated WBCs (N) are captured
by the device. Configurations C and D represent hypothetical HA devices comprised of two or
more columns with differing target specificities. The columns are arranged in parallel circuits with
independent control of the blood flow rates.
Table 2. Hemoadsorption device configurations.
HA Specificity
Configuration Column 1 Column 2 Column 3
A TNF, IL-6, IL-10 - -
B N, TNF, IL-6, IL-10 - -
C N TNF, IL-6, IL-10 -
D N TNF, IL-6 IL-10
2.10. Model Predictive Control
A nonlinear MPC (NMPC) algorithm was implemented using HA device flow rate(s) as
the manipulated variable(s); the controlled variables were activated phagocytes (N); damage (D);
and circulating cytokine levels IL-6, TNF and IL-10. The reference trajectory was defined by the
system response to a 3 mg/kg endotoxin dose, which is uniformly survivable without treatment.
More precisely, let ~x nul(p0, t) be the system state at time t following an endotoxin dose of p0 mg/kg
and null treatment. The reference for the controlled variable i at step k is defined:
~Ri(k) =
(
xnuli (3, tk), x
nul
i (3, tk+1), . . . , x
nul
i (3, tk+p−1)
)
.
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The NMPC objective function was:
min
~u(k|k)
‖Γy
(
~X(k + 1|k)− ~R(k + 1)
)
‖22 + ‖Γu~U(k|k)‖22 + ‖Γ∆u∆~U(k|k)‖22 (30)
s.t. 0 ≤ ~U(k|k) (31)
c
∑
j=1
~Uj(k|k) ≤ umax = 1.2 mL/min ∀m (32)
These terms penalize predicted error in the controlled variable (~X) from the reference (~R), changes
in the flow rates (∆~U), and the use of large HA flow rates (~U) when the effect is negligible. Standard
statistical notation is employed throughout (prediction at time k + 1 given information up to time k).
Weights for each controlled variable i are given by:
γx,i =
200
max24t=0{xnuli (3, t)}
Weights for manipulated variables are given by: Γ∆u = 1/(umax
√
c)I and Γu = 1/(4umax
√
c)I,
where c is the number of independent adsorption columns in the HA device. The size of ~U(k|k)
was m ∗ c, with the HA configuration establishing the number of adjustable flow rates. Flow rates
were constrained to be non-negative, while the sum of flows was constrained to be less than
umax = 1.2 mL/min.
The MPC time step was ∆t = 1 h, the prediction horizon was p = 4 steps, and the move
horizon was m = 2. Control simulations were also performed with p = 6 and m = 3, but no
substantial difference in performance was observed. Predicted trajectories were based on the
deterministic endotoxemia model coupled to an HA device model with n = 20 or n = 5 discretizations
(five discretizations used in conjunction with PF). Constrained minimization was performed using
fmincon in MATLAB with multiple initializations at each time step.
NMPC was performed with and without state estimation. In the former case, the full system state
was passed to the controller at each time step (Figure 2B). In the later, state estimates based on serial
cytokine measurements were generated by a PF algorithm (Figure 2C).
2.11. HA Performance Metric
HA performance was evaluated by a relative absolute error (RAE) metric, defined with respect to
the reference trajectory, and relative to a null treatment simulation:
RAEHA =
1
5 ∑i∈C
∑t |xi(p0, t)− xnuli (3, t)|
∑t |xnuli (p0, t)− xnuli (3, t)|
(33)
Here x is the model trajectory with MPC of HA, xnul is the model trajectory without treatment,
and p0 is the initial endotoxin dose. C is the set of controlled states in the endotoxemia model: N(t),
D(t), [IL− 6](t), [TNF](t), and [IL− 10](t). In the case of stochastic simulations, RAEHA is reported
as the average of N = 8 simulations.
2.12. Particle Filter State Estimation
PF was implemented according to a standard algorithm [59]. Each particle was simulated
by the stochastic endotoxemia model coupled to an HA device model with n = 5 discretizations.
Particles were initialized with a random endotoxin dose of 3–12 mg/kg, and simulated for a random
interval of 0–6 h before the first observation.
Cytokines IL-6, TNF and IL-10 were sampled hourly, with observations generated as previously
described. Samples were collected 20 min prior to each control step to mimic laboratory processing
time. Based on the observation, particles were weighted and resampled at the sampling timepoint.
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Particles were then simulated up to the control step before state estimates were computed and passed
to the MPC unit.
PF was modified to generate an estimate of time elapsed since endotoxin administration.
Each particle was assigned a variable to track its internal time. The elapsed time was estimated
by the weighted average of internal particle times. Elapsed time estimates permits the MPC to compare
predicted trajectories to the reference trajectory.
2.13. State Estimation Performance Metric
The accuracy of PF state estimation was quantified by relative absolute error (RAE) of the state
estimate with respect to the true state:
RAEPF =
1
7 ∑i∈S−p
∑24t=t0 |x˜i(p0, t)− xi(p0, t)|
∑24t=t0 |xi(p0, t)|
, (34)
where t0 is the first observed time point, x˜ is the state estimate, x is the true state, and S−p is the set of
states in the endotoxemia model excluding P.
3. Results
3.1. Parameter Sensitivity Analysis
A parametric relative sensitivity matrix (RSi,j) was generated using the finite difference method
as described in Section 2.3. The matrix was comprised of 8 rows (i ∈ [1, 8]), representing the states,
and 40 columns (j ∈ [1, 40]), representing all the parameters of the model. A graphical representation
of the RSi,j values is provided in Figure 3. The x-axis lists parameters by number; this mapping is
provided in Table 3. Each of the subplots in Figure 3 represent the parametric relative sensitivity values
corresponding to a particular state (as shown in figure sub-titles). A higher RSi,j value indicates the
state is more sensitive to the specified parameter.
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Figure 3. Parametric relative sensitivity analysis of the inflammation model for the eight model states.
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Table 3. Parameter mapping in the inflammation model.
No. Parameter No. Parameter No. Parameter No. Parameter
1 dp 11 kNTNF 21 kIL6 31 kIL10IL6
2 kN 12 kNIL6 22 dIL6 32 xIL10IL6
3 xN 13 kD 23 xIL6 33 kIL10
4 dN 14 dD 24 xIL6IL10 34 dIL10
5 kNP 15 xD 25 kIL6IL6 35 xIL10
6 kND 16 kCA 26 xIL6IL6 36 sIL10
7 xNTNF 17 dCA 27 kTNF 37 xIL10IL10
8 xNIL6 18 sCA 28 dTNF 38 kIL10Y
9 xNCA 19 kIL6TNF 29 xTNFCA 39 dIL10Y
10 xNIL10 20 xIL6TNF 30 xTNFIL6 40 xIL10Y
In order to investigate the interactions between the various states of the proposed model,
the parameters were grouped according to their association with each state, as indicated in Table 4.
In Table 5, the contributions of each of these parameter groups, in terms of percentage relative
sensitivity (%RS), to a particular state are listed. The %RS of a parameter group for each state is
calculated by taking the sum of the relative sensitivity of each parameter in that particular group
divided by the sum of relative sensitivity of the entire parameter set (M = 40) for that specific state.
Table 4. Parameters grouped according to their state association.
Parameter Groups Parameters
θP dp
θN kN , xN , dN , kNP, kND, xNTNF, xNIL6, xNCA, xNIL10, kNTNF, kNIL6
θD kD, dD, xD
θCA kCA, dCA, sCA
θIL6 kIL6TNF, xIL6TNF, kIL6, dIL6, xIL6, xIL6IL10, kIL6IL6, xIL6IL6
θTNF kTNF, dTNF, xTNFCA, xTNFIL6
θIL10 kIL10IL6, xIL10IL6, kIL10, dIL10, xIL10, sIL10, xIL10IL10
θYIL10 kIL10Y , dIL10Y , xIL10Y
Table 5. Percentage relative sensitivity (%RS) of grouped parameters for each state.
States Relative Sensitivity (%)
θP θN θD θCA θIL6 θTNF θIL10 θYIL10
P(t) 100 0 0 0 0 0 0 0
N(t) 13.8 64 0.2 1.9 2.8 5.7 11 0.5
D(t) 11.8 41.0 28.7 1.6 2.4 4.9 9.4 0.3
CA(t) 13.0 45.8 0.1 23.3 2.3 5.1 10.0 0.2
[IL6](t) 5.4 17.0 7.0 1.4 36.3 5.1 23.3 4.6
[TNF](t) 9.8 23.9 0.3 21.2 3.9 33.3 7.3 0.2
[IL10](t) 8.5 31.0 30.8 1.1 3.5 3.9 8.0 12.9
YIL10(t) 8.7 29.6 33.2 1.1 1.6 3.6 6.9 15.3
It is evident from the %RS values of Table 5 that each state is sensitive to changes in its own
parameters and the parameters associated with states P(t) (as endotoxin is the initiator) and N(t)
(as activated phagocytic cells are the primary driving force of the inflammatory action). In addition,
the individual states are variably sensitive to other states when measured directly. The dynamics
of the activated phagocytic cells, N(t), are more sensitive to parameter changes associated with
[IL10](t) (θIL10) than to those of [IL6](t) (θIL6) and [TNF](t) (θTNF). State [IL6](t) also demonstrates
higher sensitivity to parameters associated with [IL10](t) (θIL10) than [TNF](t). For the [TNF](t)
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state, sensitivities to parameters associated with CA(t) (θCA ) are dramatically higher than [IL6](t)
(θIL6) and [IL10](t) (θIL10). The [IL10](t) state and the unobserved filter, YIL10(t) are primarily
sensitive to parameters associated with D(t) (θD) and the parameters of the unobserved state,
YIL10(t). Other cytokine state parameters show lower sensitivity to [IL10](t) directly, meaning systemic
anti-inflammatory response is accomplished through secondary effects of [IL10](t) on N(t) and D(t).
3.2. Controlling the Inflammatory Response
3.2.1. MPC Using HA
To establish the upper performance bound of MPC using HA, endotoxemia was simulated using
the deterministic model and assuming the controller observes the full state space without noise. MPC of
HA was simulated using four device configurations described in Table 2. Endotoxin was administered
in 8 or 12 mg/kg doses and HA intervention began immediately at t = 0 or after delays of 1–6 h.
The reference trajectory was defined by the model response to a small endotoxin dose (3 mg/kg),
without intervention.
Figure 4 plots MPC performance for each combination of dose, intervention time, and HA
device configuration. Performance is quantified by relative absolute error (RAEHA, Equation (33)),
which measures the absolute error of the HA model trajectory (versus the reference trajectory) relative
to the absolute error of the null treatment trajectory. Performance declines when intervention is delayed
since error is calculated from t = 0 through 24 h.
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Figure 4. HA performance is measured by relative absolute error, RAEHA, calculated from time
of intervention through 24 h. RAEHA = 0 implies perfect control, while RAEHA = 1 indicates
the controller performed no better than null treatment. The x-axis corresponds to the time of HA
intervention, where t = 0 is the time of endotoxin administration. Control simulations were based on
the deterministic endotoxemia model (solid lines) or stochastic model with PF state estimation (dashed
lines). Panels correspond to HA device configurations in Table 2. (A) Configuration A, which captures
cytokines only, performs poorly. Configurations that capture white blood cells, (B–D), perform well.
Hypothetical multi-channel HA devices with differential specificity (C,D) do not substantially improve
performance over (B). In all cases, HA performance declines when treatment is delayed.
3.2.2. HA Efficacy: Cytokine Versus WBC Capture
To evaluate the contribution of WBC capture, we simulated the HA device with and without WBC
capture. Configuration A implements a device that captures cytokines only, while B is a device that
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captures both WBC and cytokines. Figures 5 and 6 plot simulation trajectories with and without HA
treatment following a 12 mg/kg endotoxin dose.
The cytokine-only device is able to drive circulating IL-6 levels to the reference, but does not
substantially impact other cytokines, activated phagocytes (N), or tissue damage (D). In contrast,
the cell capture device has the capacity to drive the inflammatory response to the reference trajectory.
Figure 4 shows that MPC performance with WBC capture (panel B) is a substantial improvement
over cytokine-only capture (panel A) across a range of doses and intervention times. Average RAEHA
over dose and intervention time was 0.83 for the cytokine-only device versus 0.40 for the WBC
capture device.
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Figure 5. Simulated endotoxemia with model predictive control (MPC) of HA device A (blue) or null
treatment (red). Device A captures cytokines but not WBC. MPC guides IL-6 levels close to the target
trajectory, but other cytokines, activated phagocytes (N) and tissue damage (D) are not substantially
impacted. Endotoxin dose was 12 mg/kg and HA intervention began immediately at t = 0.
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Figure 6. Simulated endotoxemia with MPC of HA device B (blue) or null treatment (red). MPC with
device B, which captures both cytokines and WBC, is able to guide the inflammatory state to the
reference trajectory. Endotoxin dose was 12 mg/kg and HA intervention began immediately at t = 0.
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3.2.3. Differential Capture of Inflammatory Mediators
HA efficacy could be improved by achieving differential capture of inflammatory mediators.
We designed two hypothetical devices composed of two or more HA columns arranged in a parallel
circuit. Each column is designed to capture a specific subset of cytokines or WBCs. Blood flows
through the columns are independently controlled, enabling selective removal of mediators by HA
under MPC. Configuration C has one column designed to capture WBCs, while the second column
captures all cytokines. Configuration D is composed of three columns with specificity to WBCs; TNF
and IL-6; and IL-10, respectively.
Figure 7 shows sample control schemes for each HA configuration following a 12 mg/kg
endotoxin dose and immediate intervention. With device C, MPC divides the blood flow between the
WBC capture column and the cytokine capture column at start of intervention, then both flows are
dropped to near zero within two hours. After 12 h, the flow rate to the cytokine column is increased to
reduce the circulating levels of cytokines. Device D, splits the early flow rate between WBC capture
and TNF/IL-6 capture. At two hours, the controller stops flow to WBC and TNF/IL-6 devices and
increases flow to the IL-10 device.
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Figure 7. Trajectories of manipulated variables for the device configurations in Table 2; panel labels
correspond to device configurations. Response is to a 12 mg/kg endotoxin simulation with immediate
HA intervention. Higher HA flow rates are required to achieve control without A vs. with B WBC
capture. Differential column configurations C and D demonstrate time-dependent HA column flow for
separate columns.
Panels C and D of Figure 4 plot the performance of differential capture devices across a range of
doses and intervention times. As a point of reference, panel B shows the indiscriminate device with
cytokine and WBC capture. The differential capture devices performed slightly better on average than
the indiscriminate device. Average RAEHA was 0.40, 0.379 and 0.386 for device B, C and D, respectively.
3.2.4. Particle Filter State Estimation
We implemented a PF state estimation algorithm and tested the performance in silico.
The stochastic endotoxemia model was stimulated with a randomized dose of endotoxin ranging
from 3-12 mg/kg. The time to HA intervention was randomized from 0–6 h. Dose and intervention
time was hidden from the PF to replicate conditions expected in a clinical setting. Cytokine states
IL-6, TNF and IL-10 were observed in one hour intervals through a log-normal noise distribution.
Figure 8 shows a sample simulation with PF state estimation.
The PF was initialized with various numbers of particles, from 16 to 16,384, and 36 randomized
endotoxin trials were simulated for each case. Accuracy was measured by the average relative absolute
error, RAEPF, across all endotoxin model states, excluding the endotoxin variable, P. We chose to
exclude P due to rapid elimination, which amplified small absolute errors into large relative errors.
Median RAEPF converged to ≈0.08 around 256 particles, but outliers with larger error remained
until the PF contained 2048 particles (data not shown). We chose N = 4096 particles for the following
simulations, favoring accuracy over fast computations.
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Figure 8. An example of particle filter state estimation on simulated data. circles mark observed
cytokine measurements, error bars indicate the standard deviation of the state estimate, lines show the
true model state.
3.2.5. Hemoadsorption Control with State Estimation
We developed and tested a framework for realtime control of HA based on MPC and PF state
estimation. A schematic of the in silico experiment is shown in Figure 2C. The rat subject was
simulated using the stochastic endotoxemia model coupled to the HA device model. Cytokines were
sampled once per hour, 20 min prior to the following control step. At each control step, the PF
generated a state estimate for MPC computations. MPC with state estimation was simulated for
each combination of 8 and 12 mg/kg endotoxin doses; 0, 1, 2, 4, or 6 h intervention delays; and the
four HA device configurations. Endotoxin dose and intervention delay were not provided to the PF
and MPC algorithms. A sample trajectory of MPC of HA with a 12 mg/kg endotoxin challenge and
2 h intervention delay is shown in Figure 9.
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Figure 9. Sample simulation of the stochastic endotoxemia model with MPC of HA (blue) or null
treatment (red). State estimates based on noisy cytokine measurements were generated by PF.
Endotoxin dose was 12 mg/kg with intervention at 2 h. HA was applied using configuration D.
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Performance of MPC with PF state estimation (stochastic subject with partial, noisy observations)
was compared to MPC without state estimation (deterministic subject with complete,
perfect observations). MPC with PF has reduced performance across the range of doses, intervention
times and HA devices (Figure 2). However, performance is substantially better than the null treatment
control. Our results demonstrate that the control framework is robust to a variety of confounding
variables, including process noise, partial and noisy observations, and uncertainty in endotoxin dose
and administration time.
4. Discussion
This work presents and analyzes an 8-state differential equation model of the acute inflammatory
response system [27], explicitly representing the dynamics of a variety of specific cytokines that were
treated as more abstract factors in previously developed 3-state model of the acute inflammatory
response to pathogen or endotoxin. The present focus is analyzing the dynamics of this more detailed
model to identify model structures that are consistent, in a least-squares sense, with longitudinal
rat experimental data for 3 of the 8 state variables, which were measured following endotoxin dose
challenges at 3, 6, and 12 mg/kg. The model also described the time course of the unobserved activation
of phagocytic cells by endotoxin, as well as unaccessible variables, like tissue damage (D) caused by
the activated phagocytic cells and the slow-acting anti-inflammatory mediator (CA). The data and
the resulting model response display significant nonlinearity across the three challenge levels [27].
Hence, the accurate prediction of the intermediate dose without the need for additional parameters
or parameter value changes supports the validity of the model structure, as well as its interpolative,
and possibly extrapolative, utility.
4.1. Trading Off Biological Fidelity and Model Structure
Improving biological fidelity and reproducing data accurately were of prime importance in this
work; care was taken that the added complexity reflected known inflammatory physiology. This came
at a cost of a considerable increase in the number of equations and parameters. This exercise is
representative of the ongoing challenge of balancing biological fidelity, often yielding large equation
dimension and highly parameterized models, with accuracy of, and confidence in, model parameters
based on fits to experimental data. Unlike chemical or physical interactions, which are generally
well characterized, biological interactions are often poorly quantified and causality is often not
established with certainty. Hence, the problem of synthesizing and identifying the simplest system
that can be expected to provide reasonable quantitative predictions is difficult and pervasive.
System simplicity can be debated on (non)linear, dimensional, and parametric grounds, even without
the added complexity of dynamics. In the present case, we opted to minimize the number of
state variables and to avoid explicit time delays; the price was increased nonlinearity in the model.
The Hill-type nonlinearities in (15), for example, were used to approximate a time delay rather than
using a hard-to-identify model parameter. The alternatives, including additional intermediate states
(first-order filter equations) or explicit delays would have significantly reduced the need for Hill
equation-type nonlinearities at the cost of state dimension and parameter identification complexity.
It could also be argued that our use of sigmoidal activation functions is not rooted on any demonstrable
cooperativity phenomena. In their favor, these functions avoid the use of pure delays, which present
additional challenges to simulators and optimization algorithms, without significantly increasing
the number of parameters that must be identified. Sigmoids also recapitulate, in a heuristic fashion,
biological constraints imposed by limited numbers of downstream molecular effectors (such as cell
surface receptors) and thus, saturation of effect, as well as competition for limited pools of energy and
chemical substrates.
Beyond model structure is the evaluation of model performance; how well does the model fit
or predict the data? The present model generates substantially better fits than those obtained with
our previous models [14,47]. A critique of our fitting efforts could be our lack of a 12-h time point,
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which would allow for a better characterization of the later phase of the inflammatory dynamics.
Unfortunately, it was impractical to maintain personnel overnight for that purpose. In synthesizing
the model, we found that appropriate interdisciplinary input, from expert inflammation biologists
and experimentalists, was of great value in determining appropriate experimental time points and
in defining heuristically appropriate behavior of the model. The term “heuristically appropriate”
refers to the process of defining biologically motivated or consistent accessory constraints to assist
the parameter estimation process. For example, since all animals survived the insult, we imposed the
constraint that damage asymptotically returned to zero. As a result, we have not characterized the
transition in endotoxin dose that would shift the behaviors from clearing the challenge and returning to
health (guaranteed for the selected value of dP) to endotoxin-induced death. While this is a limitation
of the proposed model, the ability to quantitatively capture the response of cytokines as a function of
time after a range of endotoxin challenges provides an advance beyond existing models. Similar to
the requirement that damage return to zero, parameter ranges explored by the fitting algorithm
were restricted based on inferences from the literature or expert opinion. In cases where our data
could not be used to support parameters/functionality, such as characterizing the damage-induced
transition from survival to death through a (non)linear function of D(t), we have not incorporated
such functionality in the model. Those continuing to look at the endotoxin challenge problem therefore
have a jumping-off point for a model that can be further extended to non-survivor cases.
A second concern in mapping a model such as the one developed here into a clinical
application is the requirement that pathogen clear. The clearance rate for endotoxin, dP, was fixed,
and endotoxin itself did not lead to additional P. In a bacterial infection, Equation (5) would need
an additional term to represent the ability of the invading bacteria to replicate, thereby sustaining
P(t), potentially indefinitely even in the face of an immune system response (another element not
incorporated in the present model). For these reasons, this work is limited to endotoxin challenge,
which may not readily extend to more broadly defined pathogen-induced inflammatory challenges.
In fact, our ongoing work has transitioned from endotoxin to cecal ligation and puncture (CLP) as
a more translationally-relevant inflammatory challenge. More complex models, e.g., [33], are more
representative of the sepsis challenge.
4.2. Biological Fidelity Challenges Parameter Estimation
Parameter fitting was performed using a gradient-based optimization routine. Given the nonlinear
nature and ill-posedness of parameter estimation from data for dynamic models, it can be expected
that other parameter sets could have yielded fits of similar quality. Lower (state) order models will
typically have smoother objective function surfaces due to the monotonic nonlinearities used in the
model and the smaller number of parameters requiring identification. Hence, reducing the number
of non-identifiable parameters should result in a smaller number of different parameter sets yielding
high-quality fits. Much like statistical models, parsimony may improve the chances of broader validity,
yet it usually results in a decreased ability to fit data well. However, contrary to statistical modeling,
parsimony cannot overrule biological plausibility, as broader validity of biological models is rooted in
their ability to represent mechanisms active in the biological system. Accordingly, there is no preferred
technique to reduce biologically-motivated dynamical models beyond taking advantage of time scale
differences and algebraic dependencies.
A logical first step in reducing parameter dimension in a nonlinear model is parametric sensitivity
analysis, with sensitivities calculated at all available time points. Insensitivity implies that either
the parameter is varied outside of the biologically relevant range, or the biology represented by
the insensitive parameter does not impact the outcome of interest in a significant way. Because of
the first possibility, insensitivity should not immediately dictate model reduction. High sensitivity,
on the other hand, may help guide model reduction [54], specifically when sensitivities between
two parameters are correlated. Accordingly, such prediction is most appropriate if sensitivity
is observed to be consistent across parameter sets of an ensemble of fits to a given dataset [27].
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Model reduction techniques arguably stand on firmer ground if such a consistency is observed.
The ultimate goal of our model development and fitting efforts is to create an ensemble of models
that reflect, given the variability of the observed data, the range of parameter sets that could have
generated this data (see also [27]).
In contrast to the biologically-motivated, but heuristic, approach to model structure analysis
and parameter identification discussed above, a mathematically rigorous analysis of the experiment
would have the ability to establish shortcomings in the model-data combination, leading to changes
in either the model or experiment to better couple the model and data. A formal test of a model
structure and data set for well-posedness of the parameter estimation problem is to evaluate the
a priori identifiability of the model given the data [60–62]. The theory states that a model is a priori
identifiable if, under the ideal conditions of noise free measurements and error free model structure,
the unknown parameters of the proposed model can be uniquely recovered from the measured data
collected during the experiment [60]. A variety of methods have been developed for (non)linear a
priori global identifiability, including power series [63], similarity transform [61], and differential
algebra [62,64]. The work of [64] employs Gröbner basis techniques to evaluate identifiability for
nonlinear polynomial (or rational) systems. Given the class of saturating nonlinearities used in the
present work, a detailed analysis of the proposed model via functional approximation or another
transformation is beyond the scope of the present work.
4.3. Cell Capture Is Predicted Key to HA Efficacy
Experimental studies have shown that the HA device captures cytokines in both in vivo and
ex vivo studies [29,31]. New experiments by our colleagues suggest that the HA device captures WBCs,
especially cytokine producing activated neutrophils – immune effectors cells – from both septic and
healthy blood. It remains uncertain whether the cell capture plays an important role toward improving
animal survival in sepsis studies. To examine the effect of cell capture, we simulated HA devices with
and without cell capture. Across a range of endotoxin doses and intervention times, the device with
cell capture performed significantly better than the cytokine-only device. The cytokine-only device was
able to impact IL-6 substantially, but had only a modest effect on TNF and IL-10, and very little effect on
activated phagocytes or tissue damage variables. Consequently, our model predicts that inflammatory
modulation is primarily due to cell capture, while cytokine capture plays a secondary role.
4.4. HA Devices with Differential Cytokine and WBC Capture May Have Little Benefit
Since the HA device captures a broad spectrum of soluble mediators as well as WBCs,
we speculated that device efficacy might be improved by differential capture of cells and mediators.
In sepsis, inflammation follows an early hyperreactive course followed by a late hyporeactive phase [65].
Consequently, targeted capture of pro-inflammatory cytokines in the early phase, followed by selective
capture of anti-inflammatory cytokines in the late phase, may improve treatment results. To examine
this hypothesis, we implemented two hypothetical HA devices: configuration C, with independent
capture of WBCs and cytokines; and D, with independent capture of WBCs (N), TNF/IL-6, and IL-10.
These devices were conceived as multiple HA columns arranged in parallel, with each having specificity
for a particular set of mediators. Across a range of endotoxin doses and intervention times, the
differential capture devices performed only slightly better than the simple broad spectrum device.
Thus, we conclude that differential capture devices will not substantially improve the efficacy of HA
for treatment of endotoxemia. This does not preclude the possibility that differential capture will
improve treatment of sepsis, where an active infection is present.
Ideally, a healthy response to bacterial infection involves a robust local production of cytokines at
the site of infection by surveillance cells, triggering the appropriate targeting of circulating neutrophils
and eradication of the local infection. When this ideal scenario does not play out, because local
controls are overwhelmed, or the systemic response is large, the clinical syndrome of sepsis ensues.
The evolving concept of sepsis, recently reviewed [66], insists on the importance of organ dysfunction
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as part of an unhealthy response to infection. There is strong evidence that organ dysfunction
relates to the non-local effects of both cytokines and poorly targeted neutrophils. For example,
TNF-receptor deficient animals do not experience sepsis-related renal failure [67] and individuals
with poorly functioning (or low baseline counts) neutrophils do not experience lung dysfunction
although their prognosis is not necessarily better [68,69]. Therefore, different organs fail in different
ways in severe infections and there is likely a differential contribution of cytokines and neutrophils
which is organ dependent. Our model does not represent the complexity of the interaction between
neutrophils, cytokines and organ damage. Any real life application will have to consider the possibility
of differential capture depending on clinical context (which organs are currently jeopardized).
4.5. MPC Reference Trajectory
There is no clear, biologically-motivated, optimal MPC reference trajectory in our simulations.
Forcing the system towards zero response might be counterproductive, as inflammation is necessary
for clearing infection and initiating healing. On the other hand, forcing a large inflammatory response
can result in excessive damage to tissues and organs. Our choice of reference trajectory was an attempt
to balance the necessity of inflammation for infectious control against the risk of organ damage due
to excessive inflammation. The inflammatory response to a 3 mg/kg endotoxin dose was chosen as
a representative inflammatory course that strikes a reasonable balance between these conflicting goals.
4.6. State Estimation
The extended and unscented Kalman filters (EKF, UFK) are popular state estimation techniques
applied to nonlinear models. These methods assume state estimates are normally distributed [39].
This is a poor assumption for models of sepsis, where distributions of cytokine measurements are
highly positively skewed with variance positively correlated to their mean. PF permits state estimation
in nonlinear models with arbitrary distributions. We chose PF state estimation due to its generality
and ease of implementation.
The key limitation of PF is the computational burden as the dimensionality of the system
increases. For our purposes, PF state estimation and MPC computation was fast enough for online
implementation. On a typical PC, state estimation with 4096 particles and MPC required less than
1 min of computation time per hour of simulated time. Computational cost may become prohibitive in
models with larger state spaces, where larger particle sets may be required. Future work is needed to
determine scalability to higher dimensional models of inflammation.
4.7. Real-Time Control of HA
Our simulations of real-time control of HA included a variety of confounding factors to emulate
the challenges of clinical application. Patient variability was represented by process noise in the subject
model. Observation noise and measurement delay mimicked the current state of cytokine assays
available in laboratories and clinics. Randomized endotoxin dose and intervention time accounted for
the real-life variability of inflammatory challenge and time of patient admission to care. Despite less
than ideal circumstances, performance declined only modestly in comparison to noise-free simulations.
We are cautiously optimistic, based on these results, that our framework can translate to application in
the laboratory and clinic.
4.8. Limitations
This work assumed that rapid measurements of the cytokines were available at point-of-care.
In current clinical practice, IL-6 measurements are available at the bedside within 20 min of blood
sample [70,71]. Similar assays are not yet available for other cytokines. Efforts to develop point-of-care
inflammatory profiles are underway, but the lack of complete cytokine profiles at bedside is currently
a barrier to clinical application. We did not extensively examine the impact of providing the controller
with delayed information in the various cytokine measurement channels. In real life applications,
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additional, less granular information might be available regarding unobserved states that might be of
significant help to the controller [72].
Our results are based on a rat endotoxemia model of acute inflammation. While endotoxemia
models have a long history in the experimental literature, the rapid inflammatory course is a stark
contrast to the slow course observed in clinical sepsis [28]. Endotoxin models lack an active infection
that accompanies clinical sepsis. A balanced inflammatory response must be capable of eliminating
infection, while limiting collateral organ damage due to excess response. Thus, the dynamics of sepsis
may not be adequately reproduced by a model that lacks infection. The cecal ligation and puncture
(CLP) model is considered to be more representative of sepsis. In CLP, the cecum of a test animal is
ligated and punctured. The punctured cecum leaks gut bacteria into the peritoneal space, resulting in
slow development of inflammation over the course of a day. In comparison to sublethal models,
lethal CLP leads to reduced WBC recruitment to the site of infection, while migration to the lung
increases [73]. Among other factors, dysregulated recruitment is associated with loss of chemokine
gradients during severe inflammation [74]. A complete understanding of these phenomenon will
require mathematical models that represent both infection and multiple organs. Consequently,
the results presented here may have limited applicability in clinical sepsis. The control framework
developed here is generally applicable to a wide range of equation-based models, and we plan to apply
these methods to a calibrated CLP model currently under development. Finally, despite our best efforts,
there may be biological phenomena that are not accurately represented in our endotoxemia model.
5. Conclusions
We present a biologically-inspired equation-based model of endotoxemia response including
activated phagocytic cells and cytokines. The model was fit to, and validated against, preclinical data.
A model-based control system, using hemofiltration to decrease circulating cytokines and phagocytic
cells, can modulate inflammation, while cytokine removal alone does not provide suitable reduction
in inflammatory response. The challenges in developing a data-calibrated model with biological
insight were many, leading to a generalizable approach where the development of top-down models
of biological processes that target quantitative validation and prediction should: (i) primarily reflect
known biological interactions among model components; (ii) be developed by interdisciplinary teams
where data collection is planned with modeling as a primary consideration; and (iii) apply relevant
literature and appropriate heuristics, based on experimental observations, to guide model development.
Thereafter, sensitivity and identifiability analysis-guided model reduction (both dimensional and
parametric) can be employed to reduce model complexity. Finally, ensemble creation and validation
on separate datasets are necessary steps to the formulation of biologically relevant, quantitatively
accurate dynamical models of complex processes.
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Appendix A. Model Structure Justification
Appendix A.1. Model Selection Technique
Akaike’s Information Criterion (AIC) [75] and Bayes Information Criterion (BIC) [76] were
employed to establish a quantitative comparison between the proposed inflammation model structure
and candidate simplifications. When comparing two models containing different values of M,
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the model with the lower AIC and BIC values is preferred. The value of AIC can be calculated
from the following equation [75]:
AIC = QP ln
(
R2
QP
)
+ 2M (A1)
Similarly, the value of BIC can be calculated as shown below [76]:
BIC = QP ln
(
R2
QP
)
+ Mln(QP) (A2)
AIC and BIC may be minimized over the choices of M (the number of model parameters) to
yield a trade-off between the quality of fit of the model, which lowers the sum squared error (R2,
calculated as R2N from Equation (A3) with weights σi = 1), and the model’s complexity, as measured
by M. Both are statistically-motivated methods; a slight variation in the second term of Equations (A1)
and (A2) is the difference in the two metrics. This term quantitates the model complexity, and the BIC
penalizes free parameters more strongly than the AIC does. While there are other methods for model
selection (e.g., the hierarchical likelihood ratio test, and the general likelihood ratio), these two metrics
provide advantages [77] and are used herein.
Both AIC and BIC techniques are widely used statistical methods for quantifying the trade-off
between model fit and model complexity, as measured by the total number of parameters.
While modeling biological systems where a limited number of measured data points are available,
over-fitting, over-parameterization, and the introduction of under-justified nonlinearities are significant
concerns. Parameter identifiability (a priori), estimation quality, and model uniqueness must be
addressed when complex models are developed from small data sets. In contrast, compact low
parameter count models may be structurally identifiable a priori, but they may also yield poor
predictive accuracy as measured by model fit (e.g., least-squares error). Hence, a balance should be
reached in terms of model complexity and accuracy, and AIC in conjunction with BIC provide such a
balancing metric. The remainder of this section presents a series of alternate versions of the proposed
model. Both the AIC and BIC values were calculated for each of the alternate versions and were
compared with the proposed model. In order to compute the AIC and BIC values, parameters of the
alternate version models (except parameter numbers 1, 18, and 36 from Table 3) were re-estimated.
Appendix A.2. Model Selection Comparisons
In modeling [IL6] with Equation (15), a 4th-order Hill function (N(t)4/(x4IL6 + N(t)
4)) was
introduced to capture the one hour delay in [IL6] response to endotoxin challenge. The inclusion of this
function was necessary to capture the data accurately, where accuracy is quantitated in a least-squares
sense as follows
minθ1 ...θM R
2
N ≡ ∑j=1 Ny ∑QPi=1
[ zj(ti)−yj(ti ,θ1...θM)
σij
]2
s.t. (5)− (24)
θm ≥ 0 ∀m ∈ [1, M]
(A3)
Addition of this nonlinearity increased the model complexity by one parameter (xIL6) versus
a linear-in-N(t) version of Equation (15) without a Hill function, which can be written as:
d[IL6]
dt = kIL6 · N(t) · [1+ kIL6TNF · f UPIL6TNF(t) + kIL6IL6 · f UPIL6IL6(t)]
f DNIL6IL10(t)− dIL6 · [IL6]
(A4)
A comparison of [IL6] predictions from the proposed model (Equation (15), solid line) and
an alternate version of the model, AV-1 (Equation (A4)), is provided as the dashed line in Figure A1.
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Figure A1. Model simulation comparison of IL-6 between the proposed model Equation (15) (solid line)
and its alternate versions, AV-1, Equation (A4) (dashed line) and, AV-2, Equation (A5) (dotted line),
against experimental data (circle) (mean ± SD) in response to endotoxin challenge of 3 mg/kg (top)
and 12 mg/kg (bottom).
Calculated AIC and BIC values of both models are given in Table A1. It is clear from the AIC and
BIC values and the Figure that the nonlinear model is superior to the linear-in-N(t) version.
Furthermore, any Hill function with order <4 in the [IL6] state compromised the model accuracy.
The [IL6] state with a 3rd-order Hill function can be written as:
d[IL6]
dt = kIL6 ·
(
N(t)3
x3IL6+N(t)
3
)
· [1+ kIL6TNF · f UPIL6TNF(t)
+kIL6IL6 · f UPIL6IL6(t)] · f DNIL6IL10(t)− dIL6 · [IL6]
(A5)
The prediction for model AV-2, in Equation (A5), is provided as the dotted line in Figure A1.
Once again, from Table A1 it is evident that the AIC and BIC values indicate the superiority of the
proposed model over AV-2.
The rapid rise and fall of [TNF] necessitated the use of two nonlinear terms to capture the dynamic
profile. This was primarily captured by assigning the N(t) forcing term a power of 1.5. A second effect
included was a 6th-order Hill function for f DNTNFCA(t) in Equation (19) to rapidly suppress the
[TNF] levels after a challenge. Any order lower than 6 compromised the model accuracy for TNF
production, particularly after the 2 h time point. For comparison, a simplified version (eliminating the
N(t) nonlinearity) of Equation (18) can be written as (AV-3):
d[TNF]
dt = kTNF · N(t) · f DNTNFCA(t) · f DNTNFIL6
−dTNF · [TNF]
(A6)
The [TNF] predictions from the proposed model (solid line) and AV-3 (Equation (A6), dashed
line) are provided in Figure A2. It is evident that the [TNF] dynamics predicted by AV-3 are not as
rapid as that observed in the experimental data. For structural consistency, another version of the
[TNF]-state with a Michaelis-Menten expression was formulated as follows (AV-4):
d[TNF]
dt = kTNF · N(t)
(
N(t)
xTNF+N(t)
)
· f DNTNFCA(t) · f DNTNFIL6 − dTNF · [TNF]
(A7)
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Figure A2. Model simulation comparison of TNF between the proposed model Equation (18) (solid line),
AV-3 Equation (A6) (dashed line), and AV-4 Equation (A7) (dotted line), against experimental data
(circle) (mean ± SD) in response to endotoxin challenge of 3 mg/kg (top) and 12 mg/kg (bottom).
The model prediction from AV-4 (dotted line) is also presented in Figure A2. Once again, it is
clear that a Michaelis-Menten formulation, which added an extra parameter (xTNF), is inadequate
to capture accurately the fast dynamics of [TNF]. The calculated AIC and BIC values from Table A1
reveal that the proposed model is superior to the two alternate model structures.
The dynamic profile of IL-10 response to the endotoxin challenge justifies further nonlinear
terms in the model. The 2-h data point mean value for the 12 mg/kg challenge is 3.6 times higher
than that for the 3 mg/kg challenge. To capture this nonlinear scaling, a 3rd-order Hill function
(N(t)3/(x3IL10 + N(t)
3)) was used, as shown in Equation (22). While the inclusion of this nonlinearity
added an extra parameter (xIL10), comparison with simpler models demonstrates its need. An alternate
linear (in terms of N(t)) version of the [IL10]-state can be written as follows (AV-5):
d[IL10]
dt = kIL10 · N(t) · [1+ kIL10IL6 · f UPIL10IL6(t)]
−dIL10 · f DNIL10IL10(t) · [IL10] +YIL10(t) + sIL10
(A8)
This reduced the model complexity by one parameter (xIL10). A comparison of the model
predictions from the proposed model (solid lines) and the alternate version (dashed lines) is provided
in Figure A3. It is clear that AV-5 is unable to capture the nonlinearities that exist in the [IL10] dynamics
between endotoxin dose levels of 3 and 12 mg/kg, especially during the first peak.
[IL10] dynamics after the initial peak, are affected by [IL6]. A 4th-order Hill function for the
f UPIL10IL6(t) dynamics (Equation (23)) was necessary to delay the effects of [IL6] on [IL10], as any
lower-order Hill expression resulted in a faster elimination of IL-10 after reaching the first peak thus
causing the model to under-predict the [IL10] dynamics at the 4 h time point.
The tissue damage-mediated second surge of IL-10 concentration required the use of a 6th-order
Hill function (N(t)n/(xnD + N(t)
n), where n = 6) in Equation (12). The higher-order Hill function was
necessary to accurately capture the second peak in the [IL10], which occurred after an initial decrease
as observed at the 4 h time point in the experimental data. A comparison of model predictions between
the proposed model and alternate versions of Equation (12) represented by 4th-order (n = 4), AV-7,
and 2nd-order (n = 2), AV-8, Hill functions are presented in Figure A4. It is evident that lower-order
(n < 6) Hill expressions in Equation (12) result in slower [IL10] dynamics, especially after the 4 h time
point. The calculated AIC and BIC values presented in Table A1 clearly indicate that the proposed
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model is again superior to these alternate versions, particularly for fitting the 3 mg/kg dose results.
Related to this damage-induced peak in IL-10, a data-motivated 4th order Hill function was used in
Equation (22); any lower-order Hill function proved to be inadequate to capture the second [IL10]
peak simultaneously for both endotoxin dose levels (3 and 12 mg/kg). However, such a bi-phasic
[IL10] dynamics were not observed in the studies performed by Hadley et al. in human subjects [78].
In order to better understand the disconnect between animal and human models [79] of endotoxin
response, and to improve fidelity of the proposed model, further investigation of the [IL10] dynamics
may be necessary.
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Figure A3. Model simulation comparison of IL-10 between the proposed model, Equation (22),
(solid line), AV-5 Equation (A8) (dashed line), and AV-6 Equation (A9) (dotted line),
against experimental data (circle) (mean ± SD) in response to endotoxin challenge of 3 mg/kg (top)
and 12 mg/kg (bottom).
To accurately capture the [IL10] dynamics (22) at longer times for various endotoxin challenge
levels, it was necessary to reduce the rate of elimination of IL-10 with increasing endotoxin dose
level. This was achieved by introducing the down-regulating function, f DNIL10IL10 (Equation (24)).
The down-regulation in the model is physiologically motivated by studies showing that elevated
levels of [IL10] reduce its own rate of elimination from the blood stream [51]. An alternate version of
Equation (22) without the f DNIL10IL10 function can be written as (AV-6):
d[IL10]
dt = kIL10 ·
(
N(t)3
x3IL10+N(t)
3
)
· [1+ kIL10IL6 · f UPIL10IL6(t)]
−dIL10 · [IL10] +YIL10(t) + sIL10
(A9)
Due to the absence of the f DNIL10IL10 term, AV-6 has one less parameter (xIL10IL10). Figure A3
shows the model prediction of [IL10] from AV-6 (dotted lines). Looking at the AIC and BIC
values in Table A1, once again it is clear that the proposed model Equation (22) is superior to both
alternate versions.
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Figure A4. Model simulation comparison of damage-mediated IL-10 between the proposed model
with a 6th-order Hill function in Equation (22) (solid line), AV-7 with a 4th-order Hill function in
Equation (22) (dashed line), and AV-8 with a 2nd-order Hill function in Equation (22) (dotted line)
against experimental data (circle) (mean ± SD) in response to endotoxin challenge of 3 mg/kg (top)
and 12 mg/kg (bottom).
Table A1. Calculated AIC and BIC values (based on 3 mg/kg and 12 mg/kg data) of the proposed
model and its alternate versions. Note: all base models have the same AIC and BIC values, they are
reported separately for convenient comparison of related submodels.
Model (Equation) AIC BIC
IL-6 (Equation (15)) 274.1 299.7
AV-1 (Equation (A4)) 303.3 328.2
AV-2 (Equation (A5)) 280.0 305.6
TNF (Equation (18)) 274.1 299.7
AV-3 (Equation (A6)) 282.2 307.8
AV-4 (Equation (A7)) 277.0 303.2
IL-10 (Equation (22)) 274.1 299.7
AV-5 (Equation (A8)) 290.2 315.1
AV-6 (Equation (A9)) 287.4 312.4
Effect of D on IL-10 (Equation (12)) 274.1 299.7
AV-7 279.4 305.0
AV-8 281.1 306.7
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